
A total of 370,000 Genmab shares will be repurchased by the biotech firm itself, according to a company press release.
A new share buy-back program aims to mitigate dilution of shares from warrant exercises, the firm writes.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app